Last updated: 2026-09-09 04:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.21, with a market capitalization of $74.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
$74.16M | |
$5.09 | |
$1,236.00 | |
$1.80 | |
$5.10 | |
74.84K | |
232.40K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) last closed at $5.10 as of 2026-09-08 23:31:00, unchanged from the previous close of $5.10.
During the latest regular trading session, CING traded between $1.80 and $1,236.00, with a volume of 74.84K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Cingulate Inc. (CING) moved from $5.44 to $5.21, representing a decline of 4.32% ($0.24).
The stock traded between $5.02 and $5.60 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 115.09 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.4%
CING is currently trading at $5.21, placing it 23.4% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.